ACSVL1 Inhibitors
1 drugsAbout ACSVL1
Acyl-CoA synthetase long-chain family member 1 (ACSVL1) is an enzyme that catalyzes the formation of fatty acyl-CoA, a crucial step in fatty acid metabolism. This process is essential for both fatty acid synthesis and degradation, playing a vital role in cellular energy production and lipid homeostasis.
While there is currently no genetic evidence directly linking ACSVL1 to specific diseases, its involvement in metabolic pathways makes it a relevant target for drug development. ACSVL1 represents a potentially valuable target for developing new therapeutic interventions aimed at restoring metabolic balance.
ACSVL1 is currently targeted by one FDA-approved drug, NEXLETOL, a small molecule approved in 2020 for metabolic indications. ESPERION THERAPS INC is the sole company with an approved drug for this target.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Coronary Atherosclerosis with only 1 trials.
Top Drugs
ESPERION THERAPS INC is the only company with an approved drug targeting ACSVL1.
Low competitive intensity suggests a potential opportunity, but also indicates possible challenges in target validation or market size.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets ACSVL1, using small molecule modality.
The absence of other modalities represents a whitespace opportunity for novel therapeutic approaches like antibodies or peptides.
Clinical Trials 47 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 16 | 15 | 0 | 1 | 100% |
| Phase 2 | 9 | 7 | 0 | 2 | 100% |
| Phase 3 | 14 | 10 | 0 | 4 | 100% |
| Phase 4 | 8 | 3 | 1 | 4 | 75% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved ACSVL1 drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting ACSVL1. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Drug Approval Timeline (2020 - 2020)
The first and most recent drug approval for ACSVL1 was NEXLETOL in 2020.
Recent entry indicates growing interest, but a single approval suggests the target may not be fully saturated, leaving room for innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 39 clinical trials targeting ACSVL1.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities